Cyclosporine in the treatment of idiopathic focal segmental glomerulosclerosis

Seminars in Nephrology

Volumn 23, Issue 2, 2003, Pages 234-241

  Cattran, Daniel C ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HEMATOPOIETIC TISSUE; HEMODYNAMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LONG TERM CARE; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; RECURRENCE RISK; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0037353142     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2003.50022     Document Type: Review

References (37)

1. Borel F, Feurer C, Guber HU, et al: Biological effects of cyclosporine A: A new antilymphocyte agent. Agents Actions 6:468-473, 1976
2. Meyrier A, Simon P, Perret G, et al: Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. Br Med J 292:789-792, 1986
3. Ryffel B: Pharmacology of cyclosporine. VI. Cellular activation: Regulation of intracellular events by cyclosporine. Pharmacol Rev 41:407-422, 1990
4. Haslan J, Branelles A, Laurent J, et al: The vascular permeability factor is a T-lymphocyte product Nephron 187-188, 1986
5. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2:556-560, 1974
6. Frank C, Herrmann M, Fernandez S, et al: Dominant T cells in idiopathic nephrotic syndrome of childhood. Kidney Int 57:510-517, 2000
7. Fuiano G, Conte G, Sepe V, et al: Acute effects of ciclosporin on renal hemodynamics and urinary protein excretion in patients with the nephrotic syndrome. Nephron 59:369-374, 1991
8. Zietse R, Wenting GJ, Kramer P, et al: Contrasting response to cyclosporin in refractory nephrotic syndrome. Clin Nephrol 31:22-25, 1989
9. Zietse R, Wenting GJ, Kramer P, et al: Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci (Lond) 82:641-650, 1992
10. Sharma R, Sharma M, Ge X, et al: Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular camp. Transplantation 62:1961-1920, 1996
11. Sharma R, Savin VJ: Cyclosporine prevents the increase in glomerular albumin permeability caused by serum from patients with focal segmental glomerular sclerosis. Transplantation 61:381-383, 1996
12. Tejani A, Butt K, Khawar R, et al: Cyclosporine-induced remission of relapsing nephrotic syndrome in children. Kidney Int 29:206, 1986 (abstr)
13. Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72-79, 1998
14. Rydel JJ, Korbet SM, Borok RZ, et al: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25:534-542, 1995
15. Banfi G, Moriggi M, Sabadini E, et al: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36:53-59, 1991
16. Pei Y, Cattran D, Delmore T, et al: Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 82:938-944, 1987
17. Korbet SM, Genchi RM, Borok RZ, et al: The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 27:647-651, 1996
18. Ponticelli C, Villa M, Banfi G, et al: Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34:618-625, 1999
19. Carruthers SG, Larochelle P, Haynes RB, et al: Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ 149:289-293, 1993
20. Lieberman KV, Tejani A: A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:46-63, 1996
21. Chishti AS, Sorof JM, Brewer ED, et al: Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 38:754-760, 2001
22. Waldo FB, Benfield MR, Kohaut EC: Therapy of focal and segmental glomerulosclerosis with methylprednisolone, cyclosporine A, and prednisone. Pediatr Nephrol 12:397-400, 1998
23. Singh A, Tejani C, Tejani A: One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol 12:26-32, 1999
24. Niaudet P: Steroid resistant idiopathis nephrotic syndrome and cyclosporine. Nephron 57:481, 1991
25. Cattran DC, Appel GB, Hebert LA, et al: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic syndrome Study Group. Kidney Int 56:2220-2226, 1999
26. Ponticelli C, Rizzoni G, Edefonti A, et al: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1377-1384, 1993
27. Lee HY, Kim HS, Kang CM, et al: The efficacy of cyclosporine A in adult nephrotic syndrome with minimal change disease and focal-segmental glomerulosclerosis: A multicenter study in Korea. Clin Nephrol 43:375-381, 1995
28. Walker RG, Kincaid-Smith P: The effect of treatment of corticosteroid-resistant idiopathic (primary) focal and segmental hyalinosis and sclerosis (focal glomerulosclerosis) with ciclosporin. Nephron 54:117-121, 1990
29. Meyrier A, Noel LH, Auriche P, et al: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 45:1446-1456, 1994
30. Ittel TH, Clasen W, Fuhs M, et al: Long-term cyclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 44:156-162, 1995
31. Meyrier A, Condamin MC, Broneer D: Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: Minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 35:S37-S42, 1991 (suppl 1)
32. Myers BD, Sibley RK, Newton L, et al: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590-600, 1988
33. McNally PG, Feehally J: Pathophysiology of cyclosporine A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 7:791-804, 1992
34. Palestine AG, Austin HA III, Balow JE, et al: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293-1298, 1986
35. Pei Y, Chan C, Cattran D, et al: Sustained vasoconstriction associated with daily cyclosporine dose in heart and lung transplant recipients: Potential pathophysiologic role of endothelin. J Lab Clin Med 125:113-119, 1995
36. Ingulli E, Singh A, Baqi N, et al: Aggressive, long-term cyclosporine therapy for steroid-resistant focal segemental glomeruloscerosis. J Am Soc Nephrol 5:1820-1825, 2002
37. Heaf J, Lokkegaard H, Larsen S: The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997. Nephrol Dial Transplant 14:1889-1897, 1999